Levothyroxine formulations [Design Issues]

posted by drcampos  – Brazil, 2007-04-24 06:46 (6653 d 00:28 ago) – Posting: # 689
Views: 10,267

Dear All,

I would like to evaluate the disposition of lower dosages of levothyroxine formulations, i.e 12,5 mg and 37.5 mg (new formulations). Considering the FDA Guidance it is necessary a dose of 600 mcg for avoinding baseline effect. So, the problem is the dose (48 tablets x 12.5 mcg = 600 mcg). Does someone have experience with these studies?

Regards,

Daniel

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,675 registered users;
81 visitors (0 registered, 81 guests [including 19 identified bots]).
Forum time: 07:15 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5